Who makes MK-8150 100 mg?

MK-8150 100 mg is developed by Merck Sharp & Dohme LLC.

What are the side effects of MK-8150 100 mg?

Common side effects include Headache, Fatigue, Postural orthostatic tachycardia syndrome, Conjunctivitis, Nausea, Regurgitation.

Last reviewed 2026-05-14 · How we verify

MK-8150 100 mg

Merck Sharp & Dohme LLC · Phase 1 active Small molecule Quality 20/100

At a glance

Generic name	MK-8150 100 mg
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Headache
Fatigue
Postural orthostatic tachycardia syndrome
Conjunctivitis
Nausea
Regurgitation
Application site pruritus
Common cold
Folliculitis
Neutrophil count increased
White blood cell count increased
Dizziness

Key clinical trials

A Single Rising Dose Study of MK-8150 (MK-8150-001) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-8150 100 mg CI brief — competitive landscape report
MK-8150 100 mg updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI